Article · Wikipedia archive · Last revised Jun 29, 2026

TDIQ

TDIQ, also known as MDTHIQ or MDA-CR, is a tetrahydroisoquinoline drug used in scientific research, which has anxiolytic and anorectic effects in animals. It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine, but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects. It is thought these effects are mediated via a partial agonist action at α2-adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.

Last revised
Jun 29, 2026
Read time
≈ 1 min
Length
290 w
Citations
5
Source
Wikipedia ↗
TDIQ
Clinical data
Other names6,7-Methylenedioxy-1,2,3,4-tetrahydroisoquinoline; 6,7-Methylenedioxy-THIQ; MDTHIQ; MDA-CR; "MDA-Conformationally Restricted"; MDA-THIQ; MDA/THIQ
Identifiers
  • 5,6,7,8-Tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H11NO2
Molar mass177.203 g·mol−1
3D model (JSmol)
  • c23OCOc2cc1CCNCc1c3
  • InChI=1S/C10H11NO2/c1-2-11-5-8-4-10-9(3-7(1)8)12-6-13-10/h3-4,11H,1-2,5-6H2
  • Key:JHLDJOBIUVJSTG-UHFFFAOYSA-N
  (verify)

TDIQ, also known as MDTHIQ or MDA-CR, is a tetrahydroisoquinoline drug used in scientific research, which has anxiolytic and anorectic effects in animals.12 It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine,3 but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects.4 It is thought these effects are mediated via a partial agonist action at α2-adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.5

See also

See also

References

References

  1. Young R, Rothman RB, Rangisetty JB, Partilla JS, Dukat M, Glennon RA (May 2006). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of "snacks" in mice". Pharmacology Biochemistry and Behavior. 84 (1): 74–83. doi:10.1016/j.pbb.2006.04.007. PMID 16750261. S2CID 22564648.
  2. Young R, Batkai S, Dukat M, Glennon RA (May 2006). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice". Pharmacology Biochemistry and Behavior. 84 (1): 62–73. doi:10.1016/j.pbb.2006.04.006. PMID 16750844. S2CID 12307882.
  3. Young R, Glennon RA (2002). "The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine". Pharmacology Biochemistry and Behavior. 71 (1–2): 205–13. CiteSeerX 10.1.1.670.8659. doi:10.1016/S0091-3057(01)00666-9. PMID 11812524. S2CID 16553365.
  4. Glennon RA, Young R, Rangisetty JB (May 2002). "Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline". Pharmacology Biochemistry and Behavior. 72 (1–2): 379–87. doi:10.1016/S0091-3057(01)00768-7. PMID 11900809. S2CID 33311107.
  5. Young R (2007). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential". CNS Drug Reviews. 13 (4): 405–22. doi:10.1111/j.1527-3458.2007.00022.x. PMC 6494129. PMID 18078426.